natgillin/translations-raw huggingface dataset:
In most patients whose ALL improved, there was no evidence of cancer cells left. 
Enamikul patsientidest, kellel äge lümfoblastleukeemia paranes, ei leitud enam vähirakke.
An overview of Blincyto and why it is authorised in the EU 
Ülevaade ravimist Blincyto ja ELis müügiloa väljastamise põhjendus
Blincyto is given by infusion (drip) into a vein using a pump device. 
Blincytot manustatakse veeniinfusioonina, kasutades infusioonipumpa.
It also attaches to a protein (CD3) on T cells (another type of white blood cell). 
Samuti seondub see T-rakkudel (samuti teatud leukotsüüdid) leiduva valguga CD3.
What benefits of Blincyto have been shown in studies? 
Milles seisneb uuringute põhjal Blincyto kasulikkus?
Blincyto can only be obtained with a prescription, and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood. 
Ravi sellega peab alustama verevähiga patsientide ravis kogenud arst.
Industria Química Y Farmacéutica VIR, S.A. 
Industria Química Y Farmacéutic a VIR, S.A.
Sweden Medical Valley Invest AB 
Medical Valley Invest AB
Teva Nederland B.V. 
Nederland B.V.
AMOXICILLIN SUGAR FREE 3G POWDER FOR ORAL SUSPENSION SACHETS 
AMOXICILLIN SUGAR FREE 3G POWDER FOR ORAL
Annex I List of nationally authorised medicinal products and marketing authorisation applications 
I lisa Riikliku müügiloaga ravimite ja müügiloa taotluste loetelu
Pregabalina Lupin pregabalin 
Pregabalina Lupin pregabaliin
Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for which bioequivalence vis-à-vis the EU reference medicinal product has been established 
IA lisa: Müügiloa säilitamiseks ja müügiloa taotluse jaoks soovitatud ravimid, mille bioekvivalentsus ELi võrdlusravimiga on kindlaks tehtud rahvusvaheline mittekaubandu slik nimetus
Iceland Lyfis ehf. 
Lyfis ehf.
EBASTINE ZENTIVA ebastine 
EBASTINE ZENTIVA ebastiin
Active Substance Strength Pharmaceutical Form 
Tugevus Ravimvorm Manustamisviis
Medipha Sante AMOXICILLINE MEDIPHA 1 g amoxicillin 
Medipha Sante AMOXICILLINE MEDIPHA 1 g amoksitsilliin
EBASTINE BIOGARAN ebastine 
EBASTINE BIOGARAN ebastiin
Rasagiline Brown & Burk 1mg Tablets rasagiline 
Rasagiline Brown & Burk 1mg Tablets rasagiliin
Eprosartan Hetero eprosartan 
Eprosartan Hetero eprosartaan
Erlotinib Ratiopharm erlotinib 
Erlotinib Ratiopharm erlotiniib
EBASTINE MYLAN ebastine 
EBASTINE MYLAN ebastiin
Rasagilin Micro Labs 1 mg Tabletten rasagiline 
Rasagilin Micro Labs 1 mg Tabletten rasagiliin
Annex IB: Products for which the marketing authorisations are recommended for suspension and marketing authorisation applications which do not satisfy the criteria for authorisation 
IB lisa: Ravimid, mille puhul soovitakse müügiloa taotluse peatamist, ja müügiloa taotlused, mis ei vasta müügiloa nõuetele EL/EMP
Teva UK Limited 
Ühendkuningriik Teva UK Limited
Saquinavir Accord 500 mg plėvele dengtos tabletės saquinavir 
Saquinavir Accord 500 mg plėvele dengtos tabletės sakvinaviir
Sandoz Limited 
Ühendkuningriik Sandoz Limited
Pharmaceuticals, S.L. 
Pharmaceutica ls, S.L.
rosuvastatin 
rosuvastatiin
Pregabalin-Hormosan 25 mg Hartkapseln pregabalin 
Pregabalin-Hormosan 25 mg Hartkapseln pregabaliin
TRAMADOL / PARACETAMOL BROWN & BURK 37.5 MG / 325 MG FILM-COATED TABLETS 
TRAMADOL / PARACETAMOL BROWN & BURK 37.5 MG / 325 MG FILMCOATED TABLETS
Tramadol/Paracétamol Zydus France tramadol/ paracetamol 
Tramadol/Paracétamol Zydus France tramadool/ paratsetamool
Tramadol/Paracétamol Nialex tramadol/ paracetamol 
Tramadol/Paracétamol Nialex tramadool/ paratsetamool
ebastine 
ebastiin
Finland Sandoz A/S 
Sandoz A/S
Pregabalina Merck 
Pregabalina Merck pregabaliin
Amoxicilina Brown amoxicillin 
Amoxicilina Brown amoksitsilliin
Brown & Burk UK Limited 
Ühendkuningriik Brown & Burk UK
Celecoxib Medical Valley celecoxib 
Celecoxib Medical Valley tselekoksiib
Pregabalin Merck 25 mg kemény kapszula pregabalin 
Pregabalin Merck 25 mg kemény kapszula pregabaliin
Erlotinib Zidrium erlotinib 
Erlotinib Zidrium erlotiniib
Celecoxib Hetero 
Celecoxib Hetero tselekoksiib
Celecoxib Brill Pharma 100 mg and 200 mg cápsulas duras celecoxib 
Celecoxib Brill Pharma 100 mg and 200 mg cápsulas duras tselekoksiib
eprosartan 
eprosartaan
Saquinavir Farmoz saquinavir 
Saquinavir Farmoz sakvinaviir
Pregabalin Lupin 25mg hard capsules pregabalin 
Pregabalin Lupin 25mg hard capsules pregabaliin
Erlotinib Teva Pharma erlotinib 
Erlotinib Teva Pharma erlotiniib
Saquinavir Accord saquinavir 
Saquinavir Accord sakvinaviir
Saquinavir saquinavir 
Saquinavir sakvinaviir
Sandoz Farmaceutica, S.A. 
Sandoz Farmaceutic a, S.A.
Gesellschaft mit beschränkter Haftung 
Hormosan Pharma Gesellschaft mit beschränkter Haftung
Saquinavir Accord 500 mg film-coated tablets saquinavir 
Saquinavir Accord 500 mg film-coated tablets sakvinaviir
Erlotinib PharmaSwiss erlotinib 
Erlotinib PharmaSwiss erlotiniib
tramadol/ paracetamol 
tramadool/ paratsetamool
Atovacuona/Hidroclorur o de Proguanil Teva 250 mg/100 mg comprimidos recubiertos con película EFG 
Atovacuona/Hidroclor uro de Proguanil Teva 250 mg/100 mg comprimidos recubiertos con película EFG
ERLOTINIB SANDOZ erlotinib 
ERLOTINIB SANDOZ erlotiniib
Bristol Laboratories Limited 
Ühendkuningriik Bristol Laboratories
Atovaquon/Proguanilhyd rochlorid - 1 A Pharma 62,5 mg/25 mg Filmtabletten 
Atovaquon/Proguanilh ydrochlorid - 1 A Pharma 62,5 mg/25 mg Filmtabletten
Amoxicillin Micro Labs 750 mg amoxicillin 
Amoxicillin Micro Labs 750 mg amoksitsilliin
Pharmaceutica l Form 
Ravimvorm Manustamisviis
Atovaquon/Proguanilhyd rochlorid - 1 A Pharma 250 mg/100 mg Filmtabletten 
Atovaquon/Proguanilh ydrochlorid - 1 A Pharma 250 mg/100 mg Filmtabletten
Atovacuona/Hidroclorur o de Proguanil Sandoz 250 mg/100 mg comprimidos recubiertos con película EFG 
Atovacuona/Hidroclor uro de Proguanil Sandoz 250 mg/100 mg comprimidos recubiertos con película EFG
Amoxicillin Micro Labs 250 mg amoxicillin 
Amoxicillin Micro Labs 250 mg amoksitsilliin
Germany Glenmark Arzneimittel 
Glenmark Arzneimittel GmbH
Erlotinib Vipharm 25 mg, 100 mg, 150 mg 
Vipharm S.A. Erlotinib Vipharm 25 mg, 100 mg, 150 mg
Amoxicillin Micro Labs 500 mg amoxicillin 
Amoxicillin Micro Labs 500 mg amoksitsilliin
Abacavir / Lamivudine abacavir/ lamivudine 
Abacavir / Lamivudine abakaviir/ lamivudiin
Irbesartan / Hydrochlorothiazide Micro Labs 300 mg /25 mg Filmtabletten irbesartan/ hydrochlorothiazide 
Irbesartan / Hydrochlorothiazide Micro Labs 300 mg /25 mg Filmtabletten irbesartaan/ hüdroklorotiasiid
Atovaquon/Proguanilhyd rochlorid-ratiopharm 250 mg/100 mg Filmtabletten 
Atovaquon/Proguanilh ydrochloridratiopharm 250 mg/100 mg Filmtabletten
Amoxicilline Authou amoxicillin 
Amoxicilline Authou amoksitsilliin
Abacavir/Lamivudin Mylan 
Mylan AB Abacavir/Lamivudin Mylan
Erlotinib Vipharm erlotinib 
Vipharm S.A. Erlotinib Vipharm erlotiniib
Celecoxib axcount 100 mg Hartkapseln celecoxib 
Celecoxib axcount 100 mg Hartkapseln tselekoksiib
Saquinavir Sandoz saquinavir 
SAQUINAVIR SANDOZ sakvinaviir
SAQUINAVIR SANDOZ saquinavir 
Saquinavir Sandoz sakvinaviir
Celecoxib Glenmark 100 mg Hartkapseln celecoxib 
Celecoxib Glenmark 100 mg Hartkapseln tselekoksiib
Etoricoxib PhaRes 120 mg Filmtabletten etoricoxib 
Etoricoxib PhaRes 120 mg Filmtabletten etorikoksiib
Celecoxib axcount 200 mg Hartkapseln celecoxib 
Celecoxib axcount 200 mg Hartkapseln tselekoksiib
Celecoxib Glenmark 200 mg Hartkapseln celecoxib 
Celecoxib Glenmark 200 mg Hartkapseln tselekoksiib
Erlotinib Vipharm 25 mg potahovane tablety 
Vipharm S.A. Erlotinib Vipharm 25 mg potahovane tablety
ERLOTINIB TEVA 
ERLOTINIB TEVA erlotiniib
Erlotinib Vipharm 100 mg potahovane tablety 
Vipharm S.A. Erlotinib Vipharm 100 mg potahovane tablety
Erlotinib Vipharm 150 mg potahovane tablety 
Vipharm S.A. Erlotinib Vipharm 150 mg potahovane tablety
Irbesartan/Hydrochlorot hiazide Brown & Burk 150mg/12.5mg Filmcoated tablets irbesartan/ hydrochlorothiazide 
Irbesartan/Hydrochlor othiazide Brown & Burk 150mg/12.5mg Film-coated tablets irbesartaan/ hüdroklorotiasiid
Denmark ratiopharm GmBH 
Taani ratiopharm GmBH
Etoricoxib PhaRes 90 mg Filmtabletten etoricoxib 
Etoricoxib PhaRes 90 mg Filmtabletten etorikoksiib
Etoricoxib PhaRes 60 mg Filmtabletten etoricoxib 
Etoricoxib PhaRes 60 mg Filmtabletten etorikoksiib
ERLOTINIB VIPHARM 25 mg filmtabletta 
Vipharm S.A. ERLOTINIB VIPHARM 25 mg filmtabletta
Irbesartan/Hydrochlorot hiazide Brown & Burk 300mg/25mg Filmcoated tablets irbesartan/ hydrochlorothiazide 
Irbesartan/Hydrochlor othiazide Brown & Burk 300mg/25mg Film-coated tablets irbesartaan/ hüdroklorotiasiid
Hydrochlorothiazide Micro Labs 150 mg/12.5 mg Filmtabletten irbesartan/ hydrochlorothiazide 
Irbesartan / Hydrochlorothiazide Micro Labs 150 mg/12.5 mg Filmtabletten irbesartaan/ hüdroklorotiasiid
Erlotinib Sandoz 25 mg erlotinib 
Erlotinib Sandoz 25 mg
Genepharm SA ERLOTINIB/GENEPHARM erlotinib 
ERLOTINIB/GENEPHA RM
Finland ratiopharm GmbH 
Soome ratiopharm GmbH
ERLOTINIB VIPHARM 100 mg filmtabletta 
Vipharm S.A. ERLOTINIB VIPHARM 100 mg filmtabletta
Duloxetin-Hormosan 20 mg magensaftresistente Hartkapseln duloxetine 
Duloxetin-Hormosan 20 mg magensaftresistente Hartkapseln duloksetiin
Powder for oral suspension 
SUSPENSION SACHETS
Duloxetin-Hormosan 30 mg magensaftresistente Hartkapseln duloxetine 
Duloxetin-Hormosan 30 mg magensaftresistente Hartkapseln duloksetiin
Erlotinib Sandoz 100 mg erlotinib 
Erlotinib Sandoz 100 mg
Duloxetin-Hormosan 60 mg magensaftresistente Hartkapseln duloxetine 
Duloxetin-Hormosan 60 mg magensaftresistente Hartkapseln duloksetiin
ERLOTINIB VIPHARM 150 mg filmtabletta 
Vipharm S.A. ERLOTINIB VIPHARM 150 mg filmtabletta
Duloxetine Lupin 60mg GR capsules duloxetine 
Duloxetine Lupin 60mg GR capsules duloksetiin
Duloxetin-Hormosan 40 mg magensaftresistente Hartkapseln duloxetine 
Duloxetin-Hormosan 40 mg magensaftresistente Hartkapseln duloksetiin
Duloxetine Lupin 20mg GR capsules duloxetine 
Duloxetine Lupin 20mg GR capsules duloksetiin
Atovaquon/Proguanilhyd rochlorid-ratiopharm 62,5 mg/25 mg Filmtabletten 
Atovaquon/Proguanilh ydrochloridratiopharm 62,5 mg/25 mg
Germany ratiopharm GmbH 
Luksemburg ratiopharm GmbH
Erlotinib Sandoz 150 mg erlotinib 
Erlotinib Sandoz 150 mg
Duloxetine Lupin 30mg GR capsules duloxetine 
Duloxetine Lupin 30mg GR capsules duloksetiin
Duloxetine Lupin 40mg GR capsules duloxetine 
Duloxetine Lupin 40mg GR capsules duloksetiin
Eletriptan Mylan eletriptan 
Eletriptan Mylan eletriptaan
Germany Hexal Aktiengesellschaft 
Aktiengesells chaft
Eprosartan Aristo 600 mg Filmtabletten eprosartan 
Eprosartan Aristo 600 mg Filmtabletten eprosartaan rahvusvaheline mittekaubanduslik nimetus
Hydrochlorothiazide Micro Labs 300 mg/12.5 mg Filmtabletten irbesartan/ hydrochlorothiazide 
Irbesartan / Hydrochlorothiazide Micro Labs 300 mg/12.5 mg Filmtabletten irbesartaan/ hüdroklorotiasiid rahvusvaheline mittekaubanduslik nimetus
Irbesartan/Hydrochlorot hiazide Brown & Burk 300mg/12.5mg Filmcoated tablets irbesartan/ hydrochlorothiazide 
Irbesartan/Hydrochlor othiazide Brown & Burk 300mg/12.5mg Film-coated tablets irbesartaan/ hüdroklorotiasiid rahvusvaheline mittekaubanduslik nimetus
Amoxicillin Micro Labs 1000 mg amoxicillin 
Amoxicillin Micro Labs 1000 mg amoksitsilliin rahvusvaheline mittekaubanduslik nimetus
saquinavir 
tselekoksiib
Luxembour g 
Genepharm SA
Malacomp HEXAL junior atovaquone/ proguanil 
Malacomp HEXAL junior
LABORATORIO Dr. ESTEVE, S.A. 
LABORATORIO Dr. ESTEVE, S.A. Avda.
List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states for all authorised methadone medicinal products for oral use containing povidone 
Lisa I Ravimi(te) nimetuste, ravimvormi(de), tugevus(t)e, manustamisviisi(de), müügiloa hoidja(te) loetelu liikmesriikides
METADON BIOEEL 
METADON BIOEEL methadone
Martindale Pharmaceuticals Ltd. Bampton Road Harold Hill 
Ühendkuningriik Martindale Pharmaceuticals Ltd. Bampton Road
Metadon-EP 20 mg methadone 
Metadon-EP 20 mg tabletta
Metadon-EP 5 mg methadone 
Metadon-EP 5 mg tabletta
on 24 July 2009. 
24 juulil 2009.
Ref.: EMEA/356093/2009 EMEA/H/C/1031 
Viide: EMEA/484292/2009 EMEA/H/C/1031
Treatment may continue until the disease gets worse. 
Ravi võib jätkata kuni haiguse süvenemiseni.
This prevents the cancer cells from dividing and they eventually die. 
Selle tulemusel ei saa vähirakud jaguneda ning lõpuks nad hävivad.
The patient's blood levels of white blood cells, platelets and haemoglobin should be checked before treatment, to ensure that they are above set minimum levels. 
Enne ravi tuleb kontrollida patsiendi vere leukotsüüdi-, trombotsüüdi- ja hemoglobiinisisaldust, et need ületaksid kehtestatud miinimumväärtusi.
It is also used together with cisplatin (another anticancer medicine) to treat women with cancer of the cervix, when the cancer has come back after radiotherapy, or when the disease is at an advanced stage (stage IVB: the cancer has spread beyond the cervix). 
Topotecan Actavist kasutatakse ka koos tsisplatiiniga (samuti vähiravim) emakakaelavähi raviks naistel, kellel vähk on pärast kiiritusravi taastunud, ning samuti kaugelearenenud haiguse korral (IVB staadium: vähk on levinud emakakaelast kaugemale).
It blocks an enzyme called topoisomerase I, which is involved in the division of DNA. 
See blokeerib ensüümi topoisomeraas I, mis osaleb DNA jagunemises.
Topotecan Actavis topotecan EPAR summary for the public 
Topotecan Actavis topotekaan Kokkuvõte üldsusele
For lung cancer, Topotecan Actavis is given every day for five days with a three-week interval between the start of each course. 
Kopsuvähi korral manustatakse Topotecan Actavist iga päev 5 päeva jooksul, jättes ravikuuride alguse vahele 3nädalase intervalli.
No additional studies were needed as Topotecan Actavis is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Hycamtin. 
Lisauuringuid ei olnud vaja, sest Topotecan Actavis on geneeriline ravim, mida manustatakse infusioonina ja sisaldab sama toimeainet kui võrdlusravim Hycamtin.
Treatment with Topotecan Actavis should only be given under the supervision of a doctor experienced in the use of chemotherapy. 
Ravi Topotecan Actavisega peab üksnes toimuma keemiaravi kasutamises kogenud arsti järelevalve all.
The Committee recommended that Topotecan Actavis be given marketing authorisation. 
Komitee soovitas anda Topotecan Actavisele müügiloa.
The European Commission granted a marketing authorisation valid throughout the EU for Topotecan Actavis to Actavis Group PTC ehf. 
Euroopa Komisjon andis Topotecan Actavise müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Actavis Group PTC ehf.
Because Topotecan Actavis is a generic medicine, the company has provided data from the published literature on topotecan. 
Et Topotecan Actavis on geneeriline ravim, esitas ettevõte topotekaani kohta avaldatud kirjandusest pärinevaid andmeid.
Because Topotecan Actavis is a generic medicine, its benefit and risk are taken as being the same as those of the reference medicine. 
Et Topotecan Actavis on geneeriline ravim, peetakse ravimi kasulikkust ja riske samadeks mis võrdlusravimil.
Topotecan Actavis also affects non-cancer cells, which causes side effects. 
Topotecan Actavis mõjutab ka muid rakke peale vähirakkude ning see põhjustab kõrvalnähte.
When used with cisplatin in cervical cancer, Topotecan Actavis is given as an infusion on days 1, 2 and 3 (with cisplatin given on day 1). 
Koos tsisplatiiniga emakakaelavähi raviks kasutamisel manustatakse Topotecan Actavist infusioonina 1., 2. ja 3. päeval (manustades tsisplatiini 1. päeval).
It is used when giving the original treatment again is not recommended. 
Topotecan Actavist kasutatakse juhul, kui algset ravi ei ole soovitatav korrata.
The full EPAR for Topotecan Actavis can be found here. 
Euroopa avaliku hindamisaruande täisteksti Topotecan Actavise kohta leiate siit.
This means that Topotecan Actavis is similar to a ‘reference medicine' already authorised in the European Union (EU) called Hycamtin. 
See tähendab, et Topotecan Actavis on sarnane võrdlusravimiga Hycamtin, millel juba on Euroopa Liidus müügiluba.
Other information about Topotecan Actavis: 
Muu teave Topotecan Actavise kohta
Topotecan Actavis is a powder to be made up into a solution for infusion (drip into a vein). 
Topotecan Actavis on pulber, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
What are the benefit and risk of Topotecan Actavis? 
Milles seisneb Topotecan Actavise kasulikkus ja mis riskid Topotecan Actavisega kaasnevad?
Therefore, the CHMP's view was that, as for Hycamtin, the benefit outweighs the identified risk. 
Seetõttu leidis inimravimite komitee, et nagu ka Hycamtini puhul, ületab Topotecan Actavise kasulikkus sellega kaasnevad riskid.
The dose of Topotecan Actavis to be used depends on the type of cancer that it is being used to treat and the patient's weight and height. 
Topotecan Actavise annus sõltub ravitavast vähiliigist ning patsiendi kaalust ja pikkusest.
Topotecan Actavis is a ‘generic medicine'. 
Topotecan Actavis on geneeriline ravim.
It is used on its own to treat patients with small cell lung cancer, when the cancer has relapsed (come back). 
Seda kasutatakse retsidiveerunud (taastunud) väikerakk-kopsuvähiga patsientide raviks.
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Topotecan Actavis has been shown to be comparable to Hycamtin. 
Inimravimite komitee otsustas, et Topotecan Actavise bioekvivalentsus Hycamtiniga on Euroopa Liidu nõuete kohaselt tõendatud.
Infusions should be carried out in a specialised cancer ward. 
Infusioon peab toimuma onkoloogiaosakonnas.
It contains the active substance topotecan. 
Ravim sisaldab toimeainena topotekaani.
The active substance in Topotecan Actavis, topotecan, is an anticancer medicine that belongs to the group ‘topoisomerase inhibitors'. 
Topotecan Actavise toimeaine topotekaan on topoisomeraasiinhibiitorite rühma kuuluv vähiravim.
What is Topotecan Actavis? 
Mis on Topotecan Actavis?
Why has Topotecan Actavis been approved? 
Miks Topotecan Actavis heaks kiideti?
Topotecan Actavis is an anticancer medicine. 
Topotecan Actavis on vähiravim.
For full details, see the Summary of Product Characteristics (also part of the EPAR). 
Üksikasjalik teave on esitatud ravimi omaduste kokkuvõttes, mis on samuti Euroopa avaliku hindamisaruande osa.
How is Topotecan Actavis used? 
Kuidas Topotecan Actavist kasutatakse?
How has Topotecan Actavis been studied? 
Kuidas Topotecan Actavist uuriti?
What is Topotecan Actavis used for? 
Milleks Topotecan Actavist kasutatakse?
How does Topotecan Actavis work? 
Kuidas Topotecan Actavis toimib?
It is usually confined to a single limb. 
Tavaliselt piirdub see ühe jäsemega.
• Patients or families who have any concerns should consult their healthcare professional. 
• Patsiendid või perekonnad, kellel on mingeid probleeme, peavad konsulteerima oma tervishoiutöötajaga.
The review of HPV vaccines was initiated on 9 July 2015 by the European Commission at the request of Denmark, under Article 20 of Regulation (EC) No 726/2004. 
HPV vaktsiinide ülevaate algatas 9. juulil 2015 Euroopa Komisjon Taani palvel määruse (EÜ) nr 726/2004 artikli 20 kohaselt.
Following their approval, the vaccines have been introduced in national immunisation programs in many countries. 
Pärast nende heakskiitmist on vaktsiinid paljudes riikides võetud kasutusele riiklikes immuniseerimisprogrammides.
The final stage of the review procedure was the adoption by the European Commission of a legally binding decision applicable in all EU Member States on 12/01/2016. 
Ülevaatusmenetluse viimane staadium oli Euroopa Komisjoni poolt kõigis EL-i liikmesriikides kehtiva seaduslikult siduva otsuse vastuvõtmine 12.01.2016.
In some patients they can severely affect the quality of life. 
Mõnedel patsientidel võivad need tugevalt elukvaliteeti mõjutada.
In reaching its recommendations, it also consulted a group of leading experts in the field, and took into 
Soovitusteni jõudmisel konsulteeris komitee ka valdkonna juhtivate ekspertidega ja arvestas
The review recognised that more than 80 million girls and women worldwide have now received these vaccines, and in some European countries they have been given to 90% of the age group recommended for vaccination. 
Ülevaates tõdeti, et enam kui 80 miljonit tüdrukut ja naist üle maailma on praeguseks neid vaktsiine saanud ning mõnes Euroopa riigis on neid antud 90%-le vaktsineerimise jaoks soovitatud vanuserühmas.
• CRPS and POTS are difficult to diagnose. 
• CRPS-i ja POTS-i on raske diagnoosida.
They have been reported in the general population since before HPV vaccines became available. 
Neist on üldpopulatsioonis teatatud enne, kui HPV vaktsiinid muutusid kättesaadavaks.
The syndromes are recognised to occur in the general population, including adolescents, regardless of vaccination. 
On teada, et mainitud sündroomid esinevad üldises populatsioonis, sealhulgas noorukitel, sõltumata vaktsineerimisest.
It is estimated that more than 63 million girls and women worldwide have been vaccinated with Gardasil/Silgard and more than 19 million with Cervarix. 
Hinnanguliselt on üle maailma enam kui 63 miljonit tüdrukut ja naist vaktsineeritud Gardasili/Silgardiga ja enam kui 19 miljonit Cervarixiga.
The CHMP's position was passed to the European Commission which endorsed it and issued a legally binding decision. 
Inimravimite komitee seisukoht saadeti Euroopa Komisjonile, kes kiitis selle heaks ja tegi õiguslikult siduva otsuse.
The assessment report containing the evidence supporting the Agency's review is available on EMA's website. 
Hindamisaruanne, mis sisaldab Euroopa Ravimiameti ülevaadet toetavaid tõendeid, on Euroopa Ravimiameti veebilehel.
It is recognised that in some affected girls these syndromes can be long lasting and severely impact quality of life. 
Tõdetakse, et mõnedel tüdrukutel võivad need sündroomid olla kauakestvad ja mõjutada kõvasti elukvaliteeti.
The safety of these vaccines, as with all medicines, will continue to be carefully monitored and will take into account any future new evidence of side effects that becomes available. 
Nagu kõigi ravimite puhul, jätkatakse ka nende vaktsiinide tähelepanelikult ohutuse jälgimist ja arvestatakse kõiki tulevasi uusi kättesaadavaks muutuvaid tõendeid kõrvaltoimete kohta.
Results of a large published study that showed no link between HPV vaccine and CFS were therefore particularly relevant. 
Ulatusliku avaldatud uuringu tulemused, mis ei näidanud seost HPV vaktsiini ja CFS-i vahel, olid seetõttu eriti asjakohased.
Reports after HPV vaccination consistent with what would be expected in this age group 
HPV-vastase vaktsineerimise järgsed teated on kooskõlas selles vanuserühmas oodatuga
It contains antigens (proteins that help product antibodies) against 4 types of HPV (types 6, 11, 16 and 18). 
See sisaldab antigeene (valgud, mis aitavad toota antikehi) 4 HPV tüübi vastu (tüübid 6, 11, 16 ja 18).
The Agency also consulted a group of experts in these syndromes and in neurology, cardiology and pharmacoepidemiology. 
Euroopa Ravimiamet konsulteeris samuti nende sündroomide ning neuroloogia, kardioloogia ja farmakoepidemioloogia ekspertide rühmaga.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom account detailed information received from a number of patient groups that also highlighted the impact these syndromes can have on patients and families. 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom mitmelt patsientide rühmalt saadud üksikasjalikke andmeid.
On 19 November EMA completed its review of the evidence surrounding reports of two syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women given human papillomavirus (HPV) vaccines. 
19. novembril lõpetas Euroopa Ravimiamet tõendite ülevaatamise seoses aruannetega kahe sündroomi - kompleksse regionaalse valusündroomi (CRPS) ja posturaalse ortostaatilise tahhükardia sündroomi (POTS) kohta noortel naistel, kes on saanud inimese papilloomiviiruse (HPV) vaktsiine.
It contains antigens for types 16 and 18 of the virus. 
See sisaldab viiruse 16. ja 18. tüübi antigeene.